Solid tumours: Building bridges to CAR‐T success

Immunotherapy using chimeric antigen receptor (CAR)‐engineered T‐cells has achieved remarkable impact in the treatment of selected blood cancers. However, meaningful clinical efficacy against nonhaematological malignancies has largely proven elusive. In this minireview, the main challenges to succes...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational discovery 2023-04, Vol.3 (2), p.n/a
Main Author: Maher, John
Format: Article
Language:English
Subjects:
Antigens
Blood cancer
Cancer therapies
CAR
Cells
Chemokines
Chemotherapy
chimeric antigen receptor
Clinical trials
CRISPR
Enzymes
Growth factors
Immunotherapy
Kinases
Ligands
macrophase
NK cell
Patients
solid tumour
T cell
Toxicity
Transcription factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy using chimeric antigen receptor (CAR)‐engineered T‐cells has achieved remarkable impact in the treatment of selected blood cancers. However, meaningful clinical efficacy against nonhaematological malignancies has largely proven elusive. In this minireview, the main challenges to successful CAR‐based intervention against solid tumours are considered. Obstacles are considered in four categories, namely target selection, trafficking of CAR‐engineered cells to tumour deposits, the need to overcome the physical, chemical and biological hurdles to immune effector function that operate within the tumour microenvironment and selection of the best host cells for CAR engineering. A range of pre‐clinical technologies that have been developed in an effort to overcome these issues are also surveyed. Although clinical progress comes dropping slow, rapid and continued advances in cellular engineering and manufacture, coupled with the emergence of several complementary interventions bodes well for the future success of CAR T‐cell immunotherapy of solid tumours. In contrast to blood cancers, solid tumours have largely proven refractory to CAR‐based immunotherapy. Obstacles include the lack of tumour‐specific targets, difficulty in entry and infiltration of tumour deposits and the myriad of immunosuppressive factors that operate within the tumour microenvironment. We also consider various host cell types for CAR engineering that have been proposed as alternatives to conventional T‐cells.
ISSN:2768-0622
2768-0622
DOI:10.1002/ctd2.179